Evaluation of melatonin therapy on sleep and delirium in intensive care patients

Submission date Prospectively registered Recruitment status 12/09/2003 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 12/09/2003 Completed [X] Results [] Individual participant data **Last Edited** Condition category 08/09/2008 Nervous System Diseases

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Richard Bourne

Contact details

STH NHS Trust
Critical Care
Royal Hallamshire Hospital
Sheffield
United Kingdom
S10 2JF
+44 (0)114 271 3036
richard.bourne@sth.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0059122216

Study information

Scientific Title

Study objectives

- 1. To evaluate the effect of melatonin therapy on the sleep characteristics of intensive care patients.
- 2. Secondary objectives include studying the incidence of delirium and bispectral index score between patients receiving melatonin or placebo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South Sheffield Research Ethics Committee (UK) on 09/01/03.

Study design

Single centre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Nervous System Diseases: Sleep disorders

Interventions

Melatonin versus placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

melatonin

Primary outcome measure

Sleep and delirium.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/04/2003

Completion date

30/04/2006

Eligibility

Key inclusion criteria

Patients admitted to the adult general intensive care unit with acute respiratory failure requiring mechanical ventilation and then a tracheostomy to assist weaning.

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

48

Key exclusion criteria

- 1. Expected length of stay of less than five further days
- 2. Previously treated for sleep disturbances
- 3. Not receiving target enteral feed volume or aspirates greater than 200mls
- 4. Previous history of convulsions
- 5. Psychiatric or neurological disease
- 6. Excessive alcohol consumption (equal to or greater than 50 units per week)
- 7. Recreational drug use
- 8. Sleep apnoea
- 9. Severe heart failure (NYHA III/ IV)
- 10. Sedative infusions must have been discontinued for more than 24 hours (propofol and alfentanil) or more than 36 hours (morphine and midazolam) with a Sedation Agitation Score (SAS) > 3

Date of first enrolment

01/04/2003

Date of final enrolment

30/04/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre STH NHS Trust Sheffield

Sheffield United Kingdom S10 2JF

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.doh.gov.uk

Funder(s)

Funder type

Government

Funder Name

Sheffield Teaching Hospitals - Central Campus (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2008		Yes	No